-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, July 27 News On July 23, the Symposium on the Innovation and Development of Medical Devices was held in Beijing, and the last key event of the 2021 "National Medical Device Safety Publicity Week" came to a successful conclusion
.
Xu Jinghe, deputy director of the State Drug Administration, attended the meeting and delivered a speech
.
.
Xu Jinghe, deputy director of the State Drug Administration, attended the meeting and delivered a speech
.
At the meeting, the relevant person in charge of the Medical Device Technology Review Center of the State Food and Drug Administration introduced the special review of innovative medical devices and related policies to encourage medical device innovation; the Yangtze River Delta Sub-center of the Medical Device Technology Review and Inspection Center, the Medical Device Technology Review Relevant persons in charge of the Bay Area Center respectively introduced the work carried out in the innovation and development of medical devices in the service area, and the progress of sub-center construction; the persons in charge of the artificial intelligence medical device innovation cooperation platform and the biomaterials innovation cooperation platform respectively focused on encouraging innovation measures , Work results and research progress; relevant persons in charge of Beijing Zhongguancun Life Science Park and Suzhou High-tech Zone Management Committee respectively introduced relevant policies to support medical device innovation in their respective regions; representatives of 8 medical device manufacturers shared information on encouraging medical device innovation The convenience brought by policies to enterprises, the current problems of enterprises, and suggestions for promoting the high-quality development of the industry
.
.
Xu Jinghe pointed out that innovation is the driving force of historical progress, the key to the development of the times, and the focus of the reform of China's medical device review and approval system
.
In recent years, the national drug regulatory authorities have implemented the innovation-driven development strategy, continuously promoted the innovation of the regulatory system, the reform of the review and approval system has been continuously deepened, and the rule of law and capacity building have been continuously strengthened
.
Established 4 drug and medical device technical review and inspection sub-centers, established 12 drug regulatory scientific research bases, 117 key laboratories, established 2 medical device innovation cooperation platforms, accelerated the establishment of an innovation-driven development pattern, and continued to release policy dividends
.
Since the launch of the special approval procedure for innovative medical devices, the number of innovative medical device products approved for marketing in China has reached 113, which better meets the public's demand for medical devices
.
.
In recent years, the national drug regulatory authorities have implemented the innovation-driven development strategy, continuously promoted the innovation of the regulatory system, the reform of the review and approval system has been continuously deepened, and the rule of law and capacity building have been continuously strengthened
.
Established 4 drug and medical device technical review and inspection sub-centers, established 12 drug regulatory scientific research bases, 117 key laboratories, established 2 medical device innovation cooperation platforms, accelerated the establishment of an innovation-driven development pattern, and continued to release policy dividends
.
Since the launch of the special approval procedure for innovative medical devices, the number of innovative medical device products approved for marketing in China has reached 113, which better meets the public's demand for medical devices
.
Xu Jinghe emphasized that the joint efforts of the industry and the regulatory authorities are needed to realize the transformation of China from a big country in the manufacture of machinery to a strong country in the manufacture of machinery and to better protect the public's demand for machinery
.
Enterprises should actively assume the main responsibility, strengthen the awareness of crisis and urgency, use technology to drive innovation, strive to build the enterprise into a strong innovation subject, and make positive contributions to the promotion of high-quality industrial development
.
.
Enterprises should actively assume the main responsibility, strengthen the awareness of crisis and urgency, use technology to drive innovation, strive to build the enterprise into a strong innovation subject, and make positive contributions to the promotion of high-quality industrial development
.
The meeting was organized by the Instrument Examination Center of the State Food and Drug Administration
.
The relevant departments of the State Food and Drug Administration, the National Health Health Committee of International Exchange and Cooperation Center, Chinese Academy of ICT relevant person in charge, Jilin, Shanghai, Guangdong, Sichuan and other provinces (municipalities) Medical Device Innovation service station responsible person, Beijing Relevant persons in charge of the National Food and Drug Administration, representatives of 29 medical device manufacturers, relevant persons in charge of the Chinese Society for Drug Administration, Chinese Society of Biomedical Engineering, and Chinese Society of Biomaterials, leaders of the Instrumental Inspection Center and heads of various departments, and some news media Attend the meeting
.
.
The relevant departments of the State Food and Drug Administration, the National Health Health Committee of International Exchange and Cooperation Center, Chinese Academy of ICT relevant person in charge, Jilin, Shanghai, Guangdong, Sichuan and other provinces (municipalities) Medical Device Innovation service station responsible person, Beijing Relevant persons in charge of the National Food and Drug Administration, representatives of 29 medical device manufacturers, relevant persons in charge of the Chinese Society for Drug Administration, Chinese Society of Biomedical Engineering, and Chinese Society of Biomaterials, leaders of the Instrumental Inspection Center and heads of various departments, and some news media Attend the meeting
.
Medical Network, July 27 News On July 23, the Symposium on the Innovation and Development of Medical Devices was held in Beijing, and the last key event of the 2021 "National Medical Device Safety Publicity Week" came to a successful conclusion
.
Xu Jinghe, deputy director of the State Drug Administration, attended the meeting and delivered a speech
.
.
Xu Jinghe, deputy director of the State Drug Administration, attended the meeting and delivered a speech
.
At the meeting, the relevant person in charge of the Medical Device Technology Review Center of the State Food and Drug Administration introduced the special review of innovative medical devices and related policies to encourage medical device innovation; the Yangtze River Delta Sub-center of the Medical Device Technology Review and Inspection Center, the Medical Device Technology Review Relevant persons in charge of the Bay Area Center respectively introduced the work carried out in the innovation and development of medical devices in the service area, and the progress of sub-center construction; the persons in charge of the artificial intelligence medical device innovation cooperation platform and the biomaterials innovation cooperation platform respectively focused on encouraging innovation measures , Work results and research progress; relevant persons in charge of Beijing Zhongguancun Life Science Park and Suzhou High-tech Zone Management Committee respectively introduced relevant policies to support medical device innovation in their respective regions; representatives of 8 medical device manufacturers shared information on encouraging medical device innovation The convenience brought by policies to enterprises, the current problems of enterprises, and suggestions for promoting the high-quality development of the industry
.
.
Xu Jinghe pointed out that innovation is the driving force of historical progress, the key to the development of the times, and the focus of the reform of China's medical device review and approval system
.
In recent years, the national drug regulatory authorities have implemented the innovation-driven development strategy, continuously promoted the innovation of the regulatory system, the reform of the review and approval system has been continuously deepened, and the rule of law and capacity building have been continuously strengthened
.
Established 4 drug and medical device technical review and inspection sub-centers, established 12 drug regulatory scientific research bases, 117 key laboratories, established 2 medical device innovation cooperation platforms, accelerated the establishment of an innovation-driven development pattern, and continued to release policy dividends
.
Since the launch of the special approval procedure for innovative medical devices, the number of innovative medical device products approved for marketing in China has reached 113, which better meets the public's demand for medical devices
.
.
In recent years, the national drug regulatory authorities have implemented the innovation-driven development strategy, continuously promoted the innovation of the regulatory system, the reform of the review and approval system has been continuously deepened, and the rule of law and capacity building have been continuously strengthened
.
Established 4 drug and medical device technical review and inspection sub-centers, established 12 drug regulatory scientific research bases, 117 key laboratories, established 2 medical device innovation cooperation platforms, accelerated the establishment of an innovation-driven development pattern, and continued to release policy dividends
.
Since the launch of the special approval procedure for innovative medical devices, the number of innovative medical device products approved for marketing in China has reached 113, which better meets the public's demand for medical devices
.
Xu Jinghe emphasized that the joint efforts of the industry and the regulatory authorities are needed to realize the transformation of China from a big country in the manufacture of machinery to a strong country in the manufacture of machinery and to better protect the public's demand for machinery
.
Enterprises should actively assume the main responsibility, strengthen the awareness of crisis and urgency, use technology to drive innovation, strive to build the enterprise into a strong innovation subject, and make positive contributions to the promotion of high-quality industrial development
.
.
Enterprises should actively assume the main responsibility, strengthen the awareness of crisis and urgency, use technology to drive innovation, strive to build the enterprise into a strong innovation subject, and make positive contributions to the promotion of high-quality industrial development
.
The meeting was organized by the Instrument Examination Center of the State Food and Drug Administration
.
The relevant departments of the State Food and Drug Administration, the National Health Health Committee of International Exchange and Cooperation Center, Chinese Academy of ICT relevant person in charge, Jilin, Shanghai, Guangdong, Sichuan and other provinces (municipalities) Medical Device Innovation service station responsible person, Beijing Relevant persons in charge of the National Food and Drug Administration, representatives of 29 medical device manufacturers, relevant persons in charge of the Chinese Society for Drug Administration, Chinese Society of Biomedical Engineering, and Chinese Society of Biomaterials, leaders of the Instrumental Inspection Center and heads of various departments, and some news media Attend the meeting
.
.
The relevant departments of the State Food and Drug Administration, the National Health Health Committee of International Exchange and Cooperation Center, Chinese Academy of ICT relevant person in charge, Jilin, Shanghai, Guangdong, Sichuan and other provinces (municipalities) Medical Device Innovation service station responsible person, Beijing Relevant persons in charge of the National Food and Drug Administration, representatives of 29 medical device manufacturers, relevant persons in charge of the Chinese Society for Drug Administration, Chinese Society of Biomedical Engineering, and Chinese Society of Biomaterials, leaders of the Instrumental Inspection Center and heads of various departments, and some news media Attend the meeting
.
Medical Network, July 27 News On July 23, the Symposium on the Innovation and Development of Medical Devices was held in Beijing, and the last key event of the 2021 "National Medical Device Safety Publicity Week" came to a successful conclusion
.
Xu Jinghe, deputy director of the State Drug Administration, attended the meeting and delivered a speech
.
.
Xu Jinghe, deputy director of the State Drug Administration, attended the meeting and delivered a speech
.
At the meeting, the relevant person in charge of the Medical Device Technology Review Center of the State Food and Drug Administration introduced the special review of innovative medical devices and related policies to encourage medical device innovation; the Yangtze River Delta Sub-center of the Medical Device Technology Review and Inspection Center, the Medical Device Technology Review Relevant persons in charge of the Bay Area Center respectively introduced the work carried out in the innovation and development of medical devices in the service area, and the progress of sub-center construction; the persons in charge of the artificial intelligence medical device innovation cooperation platform and the biomaterials innovation cooperation platform respectively focused on encouraging innovation measures , Work results and research progress; relevant persons in charge of Beijing Zhongguancun Life Science Park and Suzhou High-tech Zone Management Committee respectively introduced relevant policies to support medical device innovation in their respective regions; representatives of 8 medical device manufacturers shared information on encouraging medical device innovation The convenience brought by policies to enterprises, the current problems of enterprises, and suggestions for promoting the high-quality development of the industry
.
.
Xu Jinghe pointed out that innovation is the driving force of historical progress, the key to the development of the times, and the focus of the reform of China's medical device review and approval system
.
In recent years, the national drug regulatory authorities have implemented the innovation-driven development strategy, continuously promoted the innovation of the regulatory system, the reform of the review and approval system has been continuously deepened, and the rule of law and capacity building have been continuously strengthened
.
Established 4 drug and medical device technical review and inspection sub-centers, established 12 drug regulatory scientific research bases, 117 key laboratories, established 2 medical device innovation cooperation platforms, accelerated the establishment of an innovation-driven development pattern, and continued to release policy dividends
.
Since the launch of the special approval procedure for innovative medical devices, the number of innovative medical device products approved for marketing in China has reached 113, which better meets the public's demand for medical devices
.
Medicines Medicines Medicines Medical Devices Medical Devices Medical Devices.
In recent years, the national drug regulatory authorities have implemented the innovation-driven development strategy, continuously promoted the innovation of the regulatory system, the reform of the review and approval system has been continuously deepened, and the rule of law and capacity building have been continuously strengthened
.
Established 4 drug and medical device technical review and inspection sub-centers, established 12 drug regulatory scientific research bases, 117 key laboratories, established 2 medical device innovation cooperation platforms, accelerated the establishment of an innovation-driven development pattern, and continued to release policy dividends
.
Since the launch of the special approval procedure for innovative medical devices, the number of innovative medical device products approved for marketing in China has reached 113, which better meets the public's demand for medical devices
.
Xu Jinghe emphasized that the joint efforts of the industry and the regulatory authorities are needed to realize the transformation of China from a big country in the manufacture of machinery to a strong country in the manufacture of machinery and to better protect the public's demand for machinery
.
Enterprises should actively assume the main responsibility, strengthen the awareness of crisis and urgency, use technology to drive innovation, strive to build the enterprise into a strong innovation subject, and make positive contributions to the promotion of high-quality industrial development
.
Enterprise business enterprise.
Enterprises should actively assume the main responsibility, strengthen the awareness of crisis and urgency, use technology to drive innovation, strive to build the enterprise into a strong innovation subject, and make positive contributions to the promotion of high-quality industrial development
.
The meeting was organized by the Instrument Examination Center of the State Food and Drug Administration
.
The relevant departments of the State Food and Drug Administration, the National Health Health Committee of International Exchange and Cooperation Center, Chinese Academy of ICT relevant person in charge, Jilin, Shanghai, Guangdong, Sichuan and other provinces (municipalities) Medical Device Innovation service station responsible person, Beijing Relevant persons in charge of the National Food and Drug Administration, representatives of 29 medical device manufacturers, relevant persons in charge of the Chinese Society for Drug Administration, Chinese Society of Biomedical Engineering, and Chinese Society of Biomaterials, leaders of the Instrumental Inspection Center and heads of various departments, and some news media Attend the meeting
.
Healthy, healthy, healthy .
The relevant departments of the State Food and Drug Administration, the National Health Health Committee of International Exchange and Cooperation Center, Chinese Academy of ICT relevant person in charge, Jilin, Shanghai, Guangdong, Sichuan and other provinces (municipalities) Medical Device Innovation service station responsible person, Beijing Relevant persons in charge of the National Food and Drug Administration, representatives of 29 medical device manufacturers, relevant persons in charge of the Chinese Society for Drug Administration, Chinese Society of Biomedical Engineering, and Chinese Society of Biomaterials, leaders of the Instrumental Inspection Center and heads of various departments, and some news media Attend the meeting
.
